Pediatric patients with juvenile idiopathic arthritis exhibit significant reductions in lower-limb muscle power and force versus healthy peers.
Sulfasalazine treatment promotes disease inactivity and clinical remission in a majority of children with juvenile idiopathic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results